The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1521
Vonvendi - Recombinant von Willebrand Factor (online only)
The full article is available to subscribers Subscriber Login   

The FDA has approved intravenously administered recombinant von Willebrand factor (Vonvendi - Shire) for adults with von Willebrand disease (VWD) who require on-demand treatment and control of bleeding episodes. It is the first recombinant von Willebrand factor (VWF) product to become available in the US.

VON WILLEBRAND DISEASE — VWD is the most common inherited bleeding disorder; the prevalence of symptomatic VWD in the general population is about 0.1%, divided equally among men and women.1 It is characterized by a deficiency of VWF and, in severe cases, of factor VIII, the antihemophilic clotting factor. VWF is synthesized in endothelial cells and megakaryocytes; it mediates platelet activation and adhesion in flowing blood after vascular injury and stabilizes factor VIII.

VWD is subdivided into 3 types: type 1 is characterized by mild to moderate reductions in ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Vonvendi - Recombinant von Willebrand Factor (online only)
Article code: 1521f
 Electronic, downloadable article - $25